Dr. Relling, along with Dr. Strom, will continue to direct the Liver Tissue Core, which provides critical services for a large number of PAAR investigators. The purpose of this Core is to maintain a controlled, shared source of well-characterized liver tissue for research regarding drug-metabolizing enzymes (e.g. CYP3A, UGT1A1, UGT2B7), as well as related regulatory genes (e.g. PXR, CAR) expressed in hepatic tissue. The Liver Tissue Core is physically located in alarmed, monitored -70?C freezers at SJ. Availability of this Core has the following advantages: (1) quality control, standardization, and documentation of source, initial organ collection, processing, freezing, and storage; (2) quality control over subcellular fractionation procedures for isolation of microsomes, cytosol, RNA, and DNA; (3) maximal efficiency of use of tissue, e.g. cytosol, microsomes, and genomic DNA for different researchers' projects may all be isolated from the same liver tissue; and (4) centralized and confidential record-keeping for liver characteristics: e.g. drug metabolism phenotype for various cytochrome P450 enzymes, expression of splice variant transcripts, drug intake history histopathologic assessment, and germline genotypes for polymorphisms.
Showing the most recent 10 out of 372 publications
